IKNA Stock Price, Ikena Oncology, Inc. Quote, Chart

Market Summary

USD1.42+0.02

Market Closed

1.43%

IKNA Stock Price

View Fullscreen

IKNA RSI Chart

IKNA Valuation

Market Cap

68.5M

Price/Earnings (Trailing)

-0.98

Price/Sales (Trailing)

7.48

EV/EBITDA

-0.21

Price/Free Cashflow

-0.87

IKNA Price/Sales (Trailing)

IKNA Profitability

EBT Margin

-745.90%

Return on Equity

-45.12%

Return on Assets

-40.57%

Free Cashflow Yield

-114.81%

IKNA Fundamentals

IKNA Revenue

Revenue (TTM)

9.2M

Rev. Growth (Yr)

-87.92%

Rev. Growth (Qtr)

-44.43%

IKNA Earnings

Earnings (TTM)

-70.1M

Earnings Growth (Yr)

-13.55%

Earnings Growth (Qtr)

17.15%

Breaking Down IKNA Revenue

Last 7 days

10.1%

Last 30 days

14.5%

Last 90 days

3.7%

Trailing 12 Months

-77.0%

How does IKNA drawdown profile look like?

IKNA Financial Health

Current Ratio

15.85

IKNA Investor Care

Shares Dilution (1Y)

33.05%

Diluted EPS (TTM)

-1.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	17.5M	19.2M	14.0M	9.2M
2022	30.9M	27.7M	30.4M	15.6M
2021	9.4M	9.9M	10.8M	31.0M
2020	0	0	0	9.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ikena Oncology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 04, 2023	bonita david p	acquired	-	-	153,121	-
Aug 04, 2023	orbimed advisors llc	acquired	-	-	153,121	-
Jun 24, 2022	bonita david p	bought	-803,975	4.96281	-162,000	-
Jun 24, 2022	orbimed advisors llc	bought	-803,975	4.96281	-162,000	-
Jun 23, 2022	orbimed advisors llc	bought	-86,884	3.71	-23,419	-
Jun 23, 2022	bonita david p	bought	-86,884	3.71	-23,419	-
Jun 22, 2022	orbimed advisors llc	bought	-237,161	3.55	-66,806	-
Jun 22, 2022	bonita david p	bought	-237,161	3.55	-66,806	-

Which funds bought or sold IKNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	sold off	-100	-1,969,000	-	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-43,482	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-31.01	-5,046	4,991	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-42.67	-165,928	116,866	-%
May 15, 2024	Royal Bank of Canada	reduced	-93.52	-20,000	1,000	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	207	56,606	103,088	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-10.75	-125,208	225,801	-%
May 15, 2024	STATE STREET CORP	added	17.5	-123,812	685,356	-%
May 15, 2024	MORGAN STANLEY	reduced	-27.91	-64,892	70,205	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-61.53	-71,165	27,300	-%

Are Funds Buying or Selling IKNA?

Are funds buying IKNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IKNA

No. of Funds

Unveiling Ikena Oncology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	5.1%	2,469,828	SC 13G/A
Feb 14, 2024	omega fund vi, l.p.	4.7%	2,249,123	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.3%	6	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Oct 19, 2023	gilead sciences, inc.	6.7%	2,931,467	SC 13G
Sep 21, 2023	orbimed advisors llc	5.2%	2,189,111	SC 13D/A
Sep 14, 2023	orbimed advisors llc	5.5%	2,342,232	SC 13D/A
Feb 14, 2023	biotechnology value fund l p	3.8%	1,358,593	SC 13G/A
Feb 14, 2023	citadel advisors llc	5.9%	6	SC 13G/A

Recent SEC filings of Ikena Oncology, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Mar 12, 2024	S-8	Employee Benefits Plan
Mar 12, 2024	10-K	Annual Report
Mar 11, 2024	SC 13G/A	Major Ownership Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	3	Insider Trading
Feb 21, 2024	8-K	Current Report

Peers (Alternatives to Ikena Oncology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Ikena Oncology, Inc. News

Latest updates

Ikena Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-44.4%	658,500	1,185,000	2,004,000	5,313,000	5,450,000	6,402,000	382,000	3,384,000	20,216,500	3,746,000	3,549,000	3,474,000	65,000	2,829,000	3,073,000	3,227,000
Operating Expenses	9.1%	22,567,000	20,688,000	20,494,000	20,828,000	20,564,500	24,278,000	21,333,000	20,346,000	17,425,000	18,268,000	16,236,000	13,194,000	26,117,000	9,062,000	8,132,000	10,403,000
S&GA Expenses	37.4%	8,293,000	6,034,000	5,322,000	5,276,000	4,925,000	5,428,000	5,845,000	6,003,000	5,087,000	4,893,000	4,862,000	3,173,000	2,715,000	1,844,000	1,798,000	2,510,000
R&D Expenses	-2.6%	14,274,000	14,654,000	15,172,000	15,552,000	15,639,500	18,850,000	15,488,000	14,343,000	12,338,000	13,375,000	11,374,000	10,021,000	23,402,000	7,218,000	6,334,000	7,893,000
EBITDA Margin	-51.1%	-7.35	-4.86	-3.54	-3.87	-4.35	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-14,219,000	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-51.3%	-7.46	-4.93	-3.59	-3.92	-4.40	-	-	-	-	-	-	-	-	-	-	-
Net Income	-12.4%	-19,489,000	-17,343,000	-17,115,000	-14,219,000	-14,097,000	-17,338,000	-20,491,000	-16,839,000	2,797,000	-14,515,000	-12,681,000	-9,716,000	-26,051,000	-6,222,000	-5,038,000	-6,945,000
Net Income Margin	-65.4%	-7.44	-4.50	-3.27	-3.77	-4.40	-1.71	-1.77	-1.33	-1.10	-5.81	-5.51	-	-	-	-	-
Free Cashflow	-10.4%	-22,081,000	-19,997,000	-18,143,000	-19,936,000	-17,886,000	-18,350,000	-19,487,000	-19,817,000	-13,918,000	-18,174,000	-15,911,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-10.1%	173	192	215	172	152	172	190	211	228	248	262	279	294	168
Current Assets	-9.8%	161	179	201	161	141	160	178	199	216	237	252	269	283	166
Cash Equivalents	-54.9%	54.00	120	121	71.00	29.00	60.00	67.00	48.00	47.00	233	246	264	281	163
Net PPE	-63.0%	1.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00
Liabilities	-21.9%	17.00	22.00	28.00	15.00	17.00	25.00	32.00	37.00	35.00	40.00	58.00	63.00	66.00	63.00
Current Liabilities	-28.4%	10.00	14.00	19.00	12.00	14.00	22.00	25.00	29.00	25.00	27.00	31.00	31.00	30.00	28.00
Shareholder's Equity	-8.5%	155	170	155	157	135	147	159	174	193	208	203	216	228	-
Retained Earnings	-5.7%	-298	-282	-262	-245	-228	-214	-200	-182	-162	-145	-148	-133	-121	-111
Additional Paid-In Capital	0.4%	454	452	418	403	364	362	360	358	356	353	351	350	349	10.00
Shares Outstanding	0%	48.00	48.00	44.00	42.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	-	-
Float	-	-	-	-	179	-	58.00	-	-	-	-	-	297	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	16.1%	-18,304	-21,819	-19,997	-18,143	-19,784	-17,655	-17,219	-19,451	-19,784	-13,368	-17,990	-15,724	-13,170	-12,570	-7,670	-7,712	-9,874
Share Based Compensation	14.0%	2,001	1,755	1,998	1,879	2,000	1,859	1,811	1,955	1,900	1,581	1,449	1,262	885	650	418	354	375
Cashflow From Investing	-339.2%	-48,738	20,376	31,894	22,680	-10,806	10,499	35,782	20,486	-166,051	-550	-184	-187	-839	3,038	-	1.00	-117
Cashflow From Financing	-100.0%	-	60.00	38,918	-	-	1.00	24.00	575	495	236	69.00	-1,095	132,528	116,163	-	-	21.00
Buy Backs	-	-	-	-	663	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IKNA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues [Abstract]
Collaboration revenue		$ 5,313
Operating expenses:
Research and development	$ 9,645	15,552
General and administrative	5,999	5,276
Restructuring and other charges	2,582
Total operating expenses	18,226	20,828
Loss from operations	(18,226)	(15,515)
Other income (expense):
Investment income	2,114	1,296
Other income (expense)	(7)
Total other income, net	2,107	1,296
Loss before income taxes	(16,119)	(14,219)
Income tax expense	(27)
Net loss	(16,146)	(14,219)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	(265)	272
Total comprehensive loss	$ (16,411)	$ (13,947)
Net loss per share:
Net loss per share, basic	$ (0.33)	$ (0.39)
Net loss per share, diluted	$ (0.33)	$ (0.39)
Weighted-average common shares outstanding, basic	48,258,111	36,257,493
Weighted-average common shares outstanding, diluted	48,258,111	36,257,493

IKNA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 52,852	$ 119,894
Marketable securities	104,497	55,571
Prepaid expenses and other current assets	3,817	3,197
Total current assets	161,166	178,662
Property and equipment, net	864	2,335
Right-of-use asset	5,241	5,686
Deposits and other assets	5,511	5,409
Total assets	172,782	192,092
Current liabilities:
Accounts payable	1,909	2,066
Accrued expenses and other current liabilities	4,817	8,581
Operating lease liability	3,443	3,558
Total current liabilities	10,169	14,205
Long-term portion of operating lease liability	6,302	7,180
Other long-term liabilities	964	950
Total liabilities	17,435	22,335
Commitments and contingencies (Note 8)
Stockholders equity
Preferred stock, $0.001 par value - 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; No shares issued and outstanding as of March 31, 2024 or December 31, 2023
Common stock, $0.001 par value, 150,000,000 shares authorized and 48,258,111 shares issued and outstanding at March 31, 2024 and December 31, 2023	48	48
Additional paid-in capital	454,143	452,142
Accumulated other comprehensive loss	(313)	(48)
Accumulated deficit	(298,531)	(282,385)
Total stockholders' equity	155,347	169,757
Total liabilities and stockholders' equity	$ 172,782	$ 192,092

About Ikena Oncology, Inc.

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

CEO	Dr. Mark Manfredi Ph.D.
WEBSITE	https://ikenaoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	59

Ikena Oncology, Inc. Frequently Asked Questions

What is the ticker symbol for Ikena Oncology, Inc.? What does IKNA stand for in stocks?

IKNA is the stock ticker symbol of Ikena Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ikena Oncology, Inc. (IKNA)?

As of Fri May 17 2024, market cap of Ikena Oncology, Inc. is 68.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IKNA stock?

You can check IKNA's fair value in chart for subscribers.

What is the fair value of IKNA stock?

You can check IKNA's fair value in chart for subscribers. The fair value of Ikena Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ikena Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IKNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ikena Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether IKNA is over valued or under valued. Whether Ikena Oncology, Inc. is cheap or expensive depends on the assumptions which impact Ikena Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IKNA.

What is Ikena Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, IKNA's PE ratio (Price to Earnings) is -0.98 and Price to Sales (PS) ratio is 7.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IKNA PE ratio will change depending on the future growth rate expectations of investors.